Manulife Announces Exclusive Partnership with Guardant Health to Bring the Shield Multi-Cancer Detection Test to Customers Across Asia
First insurer in Asia to bring the innovative blood-based multi ‑ cancer screening solution to Hong Kong, Singapore, and the Philippines TSX/NYSE/PSE: MFC SEHK: 945 HONG KONG, SINGAPORE, and MANILA, Philippines, March 16, 2026 /PRNewswire/ --...
Guardant Health Japan receives regulatory approval of Guardant360® CDx liquid biopsy as companion diagnostic for imlunestrant in metastatic or recurrent breast cancer previously treated with endocrine therapy
Guardant360® CDx is the first companion diagnostic to be approved in Japan to identify ESR1 mutations in patients with hormone receptor-positive, HER2-negative breast cancer for treatment with imlunestrant TOKYO, Dec. 22, 2025 /PRNewswire/ --...